PDF herunterladen
PSYCH up2date 2013; 7(05): 269-284
DOI: 10.1055/s-0033-1349444
Organische psychische Störungen
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentös induzierte neuropsychiatrische Störungen

Thomas Messer
,
Oliver Strasser
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. September 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik
Kernaussagen

  • Eine große Anzahl von Medikamenten – sowohl Internistika als auch Neuropsychopharmaka – können psychische Auffälligkeiten hervorrufen.

  • Multimorbide und ältere Menschen sind für neuropsychiatrische Störungen aufgrund der Einzelsubstanzen oder als Folge von Interaktionen (Wechselwirkungen) anfälliger.

  • Delirien treten unter Pharmaka häufig maskiert auf, was die Diagnostik erschwert und die Letalität erhöht.

  • Bei substanzinduzierten affektiven Störungen muss das Suizidrisiko berücksichtigt werden.

  • Unerwünschte neuropsychiatrische Nebenwirkungen von Psychopharmaka sind selten, sollten aber wegen der möglichen nachteiligen Konsequenzen frühzeitig identifiziert und therapiert werden.

 

  • Literatur

  • 1 Prüter C. Delir. In: Block F, Prüter C, Hrsg. Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg: Springer Medizin Verlag; 2006: 386-405
    CrossrefGoogle Scholar
  • 2 Liptzin B, Levkoff SE. An empirical study of delirium subtypes. Br J Psychiatry 1992; 161: 843-845
    CrossrefGoogle Scholar
  • 3 Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140: 1048-1050
    Google Scholar
  • 4 Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing 2011; 40: 23-29
    CrossrefGoogle Scholar
  • 5 Risser A, Donovan D, Heintzman J et al. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371-1378
    Google Scholar
  • 6 Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 2001; 27: 405-425
    Google Scholar
  • 7 Slobodin G, Elias N, Zaygraikin N et al. Levofloxacin-induced delirium. Neurol Sci 2009; 30: 159-161
    PubMedGoogle Scholar
  • 8 Penttila J, Pasila K, Tiisala A et al. Delirium in an adolescent patient during treatment with cephalexin. J Adolesc Health 2006; 39: 782-783
    CrossrefGoogle Scholar
  • 9 Tome AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 2011; 34: 465-488
    CrossrefPubMedGoogle Scholar
  • 10 Brouwers EE, Sohne M, Kuipers S et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009; 29: 59-63
    CrossrefGoogle Scholar
  • 11 Bandettini di PM, Anfosso S, Audenino D et al. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci 2011; 18: 313-318
    CrossrefGoogle Scholar
  • 12 Ozsoylar G, Sayin A, Bolay H. Clarithromycin monotherapy-induced delirium. J Antimicrob Chemother 2007; 59: 331
    Google Scholar
  • 13 Alexander J, Nillsen A. Venlafaxine-induced delirium. Aust N Z J Psychiatry 2011; 45: 606
    Google Scholar
  • 14 Howe C, Ravasia S. Venlafaxine-induced delirium. Can J Psychiatry 2003; 48: 129
    Google Scholar
  • 15 Bailer U, Fischer P, Kufferle B et al. Occurrence of mirtazapine-induced delirium in organic brain disorder. Int Clin Psychopharmacol 2000; 15: 239-243
    CrossrefGoogle Scholar
  • 16 Degner D, Grohmann R, Kropp S et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 (Suppl. 01) S39-S45
    Artikel in Thieme ConnectGoogle Scholar
  • 17 Grohmann R, Ruther E, Engel RR et al. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32: 21-28
    Artikel in Thieme ConnectGoogle Scholar
  • 18 Grohmann R, Hippius H, Helmchen H et al. The AMUP study for drug surveillance in psychiatry – a summary of inpatient data. Pharmacopsychiatry 2004; 37 (Suppl. 01) S16-S26
    Artikel in Thieme ConnectGoogle Scholar
  • 19 Omata N, Murata T, Omori M et al. A patient with lithium intoxication developing at therapeutic serum lithium levels and persistent delirium after discontinuation of its administration. Gen Hosp Psychiatry 2003; 25: 53-55
    Google Scholar
  • 20 Cavallazzi R, Saad M, Marik PE. Delirium in the ICU: an overview. Ann Intensive Care 2012; 2: 49
    CrossrefGoogle Scholar
  • 21 Bender S, Grohmann R, Engel RR et al. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 2004; 37 (Suppl. 01) S46-S53
    Google Scholar
  • 22 Centorrino F, Albert MJ, Drago-Ferrante G et al. Delirium during clozapine treatment: incidence and associated risk factors. Pharmacopsychiatry 2003; 36: 156-160
    Artikel in Thieme ConnectGoogle Scholar
  • 23 Prudent M, Drame M, Jolly D et al. Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort. Drugs Aging 2008; 25: 933-946
    CrossrefGoogle Scholar
  • 24 Aggarwal A, Sharma DD. Zolpidem withdrawal delirium: a case report. J Neuropsychiatry Clin Neurosci 2010; 22: 451.e27-451.e28
    Google Scholar
  • 25 Freudenreich O, Menza M. Zolpidem-related delirium: a case report. J Clin Psychiatry 2000; 61: 449-450
    Google Scholar
  • 26 Zhao Y, Xu W, Qiu L et al. Metoprolol-induced psychosis in a young patient. Gen Hosp Psychiatry 2013; 35: 102
    Google Scholar
  • 27 Sirois FJ. Visual hallucinations and metoprolol. Psychosomatics 2006; 47: 537-538
    CrossrefGoogle Scholar
  • 28 Fisher AA, Davis M, Jeffery I. Acute delirium induced by metoprolol. Cardiovasc Drugs Ther 2002; 16: 161-165
    CrossrefGoogle Scholar
  • 29 Prüter C. Depression. In: Block F, Prüter C, Hrsg. Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg: Springer Medizin Verlag; 2006: 422-446
    CrossrefGoogle Scholar
  • 30 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 8.. Aufl. Heidelberg, Berlin: Springer Medizin Verlag; 2011
    CrossrefGoogle Scholar
  • 31 Abouesh A, Stone C, Hobbs WR. Antimicrobial-induced mania (antibiomania): a review of spontaneous reports. J Clin Psychopharmacol 2002; 22: 71-81
    CrossrefGoogle Scholar
  • 32 Abouesh A, Hobbs WR. Clarithromycin-induced mania. Am J Psychiatry 1998; 155: 1626
    Google Scholar
  • 33 Miller JM, Kustra RP, Vuong A et al. Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates, and effect of treatment with antiepileptic drugs. Drugs 2008; 68: 1493-1509
    CrossrefGoogle Scholar
  • 34 Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007; 30: 555-567
    CrossrefGoogle Scholar
  • 35 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116847
  • 36 Grunze HC. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci 2008; 10: 77-89
    Google Scholar
  • 37 Prüter C. Depressive Syndrome bei malignen Erkrankungen. In: Hegerl U, Hoff P, Hrsg. Depressionsbehandlung unter komplizierenden Bedingungen. Bremen: Uni-Med Verlag; 2003: 64-70
    Google Scholar
  • 38 Bolanos SH, Khan DA, Hanczyc M et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol 2004; 92: 500-505
    CrossrefGoogle Scholar
  • 39 Sadovnick AD, Remick RA, Allen J et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-632
    CrossrefGoogle Scholar
  • 40 Udina M, Castellvi P, Moreno-Espana J et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128-1138
    CrossrefGoogle Scholar
  • 41 Schaefer M, Engelbrecht MA, Gut O et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 731-746
    CrossrefGoogle Scholar
  • 42 Engelberg H. Low serum cholesterol and suicide. Lancet 1992; 339: 727-729
    CrossrefGoogle Scholar
  • 43 Lechleitner M, Hoppichler F, Konwalinka G et al. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lancet 1992; 340: 910
    Google Scholar
  • 44 Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-1500
    CrossrefGoogle Scholar
  • 45 Bandelow B, Muller P, Gaebel W et al. Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich. Eur Arch Psychiatry Clin Neurosci 1990; 240: 113-120
    CrossrefGoogle Scholar
  • 46 Minov C, Messer T, Schmauss M. Organische Psychosen. In: Block F, Prüter C, Hrsg. Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg: Springer Medizin Verlag; 2006: 407-420
    CrossrefGoogle Scholar
  • 47 Mulhall JP, Bergmann LS. Ciprofloxacin-induced acute psychosis. Urology 1995; 46: 102-103
    CrossrefGoogle Scholar
  • 48 Seurs L, Mierzejewska A, Claes SJ. [Corticosteroid-induced paranoid psychosis: case report and review of the literature]. Tijdschr Psychiatr 2011; 53: 37-47
    Google Scholar
  • 49 Lopez-Medrano F, Cervera R, Trejo O et al. Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin level. Ann Rheum Dis 2002; 61: 562-563
    CrossrefGoogle Scholar
  • 50 Ecker D, Unrath A, Kassubek J et al. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol 2009; 9: 23
    CrossrefGoogle Scholar
  • 51 Honey GD, Corlett PR, Absalom AR et al. Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. J Neurosci 2008; 28: 6295-6303
    CrossrefGoogle Scholar
  • 52 Haupt M. Behandlung demenzieller Erkrankungen. In: Möller HJ, Hrsg. Therapie psychiatrischer Erkrankungen. Stuttgart: Thieme; 2000: 507-541
    Google Scholar
  • 53 Bickel H. Epidemiologie der Demenzen. In: Förstl H, Bickel H, Kurz A, Hrsg. Demenzen – Grundlagen, Klinik und Therapie. Heidelberg, Berlin: Springer Medizin Verlag; 1999: 9-32
    Google Scholar
  • 54 Campbell N, Boustani M, Limbil T et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009; 4: 225-233
    Google Scholar
  • 55 Prüter C. Demenz. In: Block F, Prüter C, Hrsg. Heidelberg, Berlin: Springer Medizin Verlag; 2006: 361-383
    Google Scholar
  • 56 Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging 1994; 5: 192-199
    CrossrefGoogle Scholar
  • 57 Applegate WB, Pressel S, Wittes J et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994; 154: 2154-2160
    CrossrefGoogle Scholar
  • 58 Prince MJ. The treatment of hypertension in older people and its effect on cognitive function. Biomed Pharmacother 1997; 51: 208-212
    CrossrefGoogle Scholar
  • 59 Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 1999; 113: 420-430
    CrossrefGoogle Scholar
  • 60 Foy A, O'Connell D, Henry D et al. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol Biol Sci Med Sci 1995; 50: M99-106
    Google Scholar
  • 61 Pisani F, Oteri G, Costa C et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25: 91-110
    CrossrefGoogle Scholar
  • 62 Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352: 1112-1120
    CrossrefGoogle Scholar
  • 63 Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-713
    CrossrefGoogle Scholar
  • 64 Tune L, Carr S, Hoag E et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-1394
    CrossrefGoogle Scholar
  • 65 Strawn JR, Keck Jr PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870-876
    CrossrefGoogle Scholar